Big Concepts in Brief: What is Engineering Biology?

So, what does that mean in practice? It can mean programming microbes to act like tiny factories, producing something they wouldn’t normally make. It can mean developing new vaccines or gene therapies, creating alternative proteins, producing bio-based chemicals and materials, or finding lower-impact manufacturing routes that use renewable feedstocks and less energy. In other words, engineering biology isn’t one narrow technology. It’s a toolbox that can be applied across multiple sectors.

What is engineering biology?

At its simplest, engineering biology is the application of engineering principles to biology. That means bringing together our understanding of DNA, genes, proteins and cells with tools from process engineering, chemistry, automation, modelling and manufacturing. The aim is to design biological systems that can do useful things more effectively and at a scale that matters commercially. 

One helpful way to think about it is this: biotechnology is the broad field of using biology to create useful products and processes, while synthetic biology provides many of the tools used to design and modify biological systems. Engineering biology builds on this, bringing those tools together with engineering, process development and scale-up thinking. The focus isn’t just on whether something works in the lab, but whether it can be controlled, repeated, scaled and commercialised. That’s why engineering biology is closely linked to bioprocessing and biomanufacturing as well as discovery science. By enabling biological innovations to move into real-world production, it’s also a key foundation of the emerging bioeconomy, helping create more sustainable products, processes and industries.

How does engineering biology work?

Engineering biology works by using cells, microbes, enzymes or other biological systems to make something useful, such as a medicine, material, ingredient or chemical. Scientists and engineers design or adapt those systems, then develop a process to produce the target reliably and at scale. 

For example, a microbe can be engineered to act like a tiny factory, producing a protein for food or feed from gases such as carbon dioxide or methane in a bioreactor. Instead of relying on traditional agricultural production, the biological system is designed to make the desired ingredient in a more controlled way. 

The challenge is that proving something works in the lab is only the start. It also needs to be controlled, tested and improved so it can perform reliably in real manufacturing conditions. 

One of the main ways scientists and engineers do this is through the design-build-test-learn cycle, or DBTL. First, they design the biological system or process they want. Then they build it, test how it performs and learn from the results before refining the next version. 

By repeating that cycle, innovators can improve both the biology and the process over time, helping move an idea from early concept towards scale-up and commercialisation.

Where is engineering biology being used?

One of the most powerful things about engineering biology is its breadth. In healthcare, it’s helping enable vaccines, RNA therapies, biologics and other advanced treatment approaches. In food and agriculture, it can support alternative proteins, novel food ingredients, improved fertilisers and other routes to more resilient production systems. In chemicals and materials, it can open up lower-carbon ways to make products that currently depend on fossil feedstocks. It also has applications in fuels, recycling and circular manufacturing. 

This is why the UK Government has identified engineering biology as a strategic technology area. Its national vision describes engineering biology as the design, scaling and commercialisation of biology-derived products and services that can transform sectors or produce existing products more sustainably. That framing reflects a wider shift: engineering biology is no longer just a research topic. It’s increasingly seen as an industrial capability.

What does it take to scale engineering biology?

This is where things become more complex. A biological system can perform well in tightly controlled lab conditions and still be a long way from a commercially viable process. Scaling engineering biology means proving more than the science. It means understanding whether the process can be controlled, whether the product can be recovered and specified consistently, whether the economics work, and whether the relevant regulatory or customer requirements can be met.

Moving from early promise to real-world application often requires specialist expertise, infrastructure and development support. That’s especially true in engineering biology, where biological design, process development, scale-up and product quality all need to come together. As the field matures, progress depends not only on scientific advances, but also on having the right environment to test, refine and scale new ideas. 

This is sometimes described as the ​“missing middle” between discovery and production. It’s the stage where innovators need evidence that a process can move beyond the bench: that it’s robust, transferable and capable of supporting the critical decisions needed for commercialisation, be that regulatory, trials, further scale-up or investment. 

How is CPI helping?

CPI supports engineering biology projects across a broad range of industries, including agriculture and food technology, chemicals and materials manufacturing, health technology and pharmaceuticals. Our capabilities span design, development, optimisation and scale-up, helping bridge the gap between promising biology and real-world application. 

This includes infrastructure from 1 mL to 10,000 L for microbial fermentation, up to 200L scale for mammalian alongside capabilities such as strain, cell line and bioprocess development, modelling and simulation, upstream and downstream process development, analytical method development across process and product, pilot and demonstration-scale production, and gas fermentation. Together, these capabilities are intended to help innovators reduce scale-up risk, generate better evidence and move more confidently towards commercialisation. 

The importance of that role has been recognised more widely too. The UK Government’s national vision for engineering biology identifies CPI as a flagship facility that can help innovators develop, scale and commercialise engineering biology products and processes. In practice, that means CPI has a clear part to play in helping engineering biology move from research into application, drawing on facilities, technical expertise and development support across different stages of scale-up. 

The bigger opportunity

Engineering biology offers the chance to rethink how we make things, not just what we make. It can help create more targeted medicines, more resilient food systems, lower-impact materials and more sustainable manufacturing routes. But to capture that opportunity, innovation must move beyond the laboratory. Success depends on the ability to design, test, scale and commercialise with confidence. 

That’s why engineering biology matters now. It isn’t only a scientific concept, but a strategic industrial capability that underpins the growth of the bioeconomy. By enabling biological solutions across sectors, it has the potential to support economic growth, strengthen resilience and help tackle health and environmental challenges in practical ways. As that capability grows, the organisations that can connect ideas to industrial reality will play an increasingly important role.